STORM Therapeutics names Marguerite Hutchinson as CBO

1 November 2023

UK clinical-stage biotech STORM Therapeutics, which is targeting RNA modifying enzymes (RMEs) for oncology and other diseases, has appointed Marguerite Hutchinson as its chief business officer.

Ms Hutchinson joins STORM from Tatara Therapeutics, where she was chief executive of the UCSF spin-out which she set up and raised seed financing.

Ms Hutchinson has over 10 years’ extensive experience in leading licensing agreements and collaborations with large, high profile healthcare companies as well as experience in legal and strategic operations. She was previously the chief operating officer and general counsel of Plexxikon, a member of the Daiichi Sankyo (TYO: 4568) group, establishing and managing collaborations with Roche, Merck, AstraZeneca, Array and Cancer Research UK.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK